Pub Date : 2026-01-28DOI: 10.1158/2159-8290.cd-rw2026-014
{"title":"vCATCH Maps Cellular Targets of Cancer Drugs throughout the Entire Body.","authors":"","doi":"10.1158/2159-8290.cd-rw2026-014","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-rw2026-014","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"82 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-27DOI: 10.1158/2159-8290.cd-nw2026-0008
An AI system powered by structured oncology data matched oncologists' treatment choices in more than 90% of real clinical queries, besting a standard large language model. By focusing on a narrowly defined task-genomics-guided therapy selection-the platform demonstrates a practical pathway for deploying reliable AI tools in precision oncology.
{"title":"AI Matches Treatment Choices in Precision Oncology Tests.","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0008","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0008","url":null,"abstract":"An AI system powered by structured oncology data matched oncologists' treatment choices in more than 90% of real clinical queries, besting a standard large language model. By focusing on a narrowly defined task-genomics-guided therapy selection-the platform demonstrates a practical pathway for deploying reliable AI tools in precision oncology.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"293 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-22DOI: 10.1158/2159-8290.cd-nw2026-0007
Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs. Of the 11 patients with T-cell acute lymphoblastic leukemia who received these BE-CAR7 T cells, all had complete morphogenic remission after 28 days, 82% underwent stem-cell transplantation, and 64% remain in remission 3 to 36 months after treatment.
{"title":"Base Editing Might Be Key to CAR T-cell Therapy.","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0007","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0007","url":null,"abstract":"Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs. Of the 11 patients with T-cell acute lymphoblastic leukemia who received these BE-CAR7 T cells, all had complete morphogenic remission after 28 days, 82% underwent stem-cell transplantation, and 64% remain in remission 3 to 36 months after treatment.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"58 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-22DOI: 10.1158/2159-8290.cd-rw2026-011
{"title":"Surface Protein AQP5 Is a Functional Marker of Gastric Cancer Stem Cells.","authors":"","doi":"10.1158/2159-8290.cd-rw2026-011","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-rw2026-011","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"51 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune check blockade (ICB). In a Phase 1a study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR, unconfirmed) is 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC) the ORR (unconfirmed) was 33.33% in the 1000-1200mg cohort. This study supports the clinical potential of RNK08954 in patients with KRAS G12D mutation either as a single agent or in combination.
{"title":"Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor.","authors":"Ling Xie,Chunwei Xu,Han Si,Xiaoshuang Fu,Xiangcai Yang,Jianan Jin,Xiaoqing Yu,Zhiying Shao,Yanling Wang,Tianqing Chu,Jun Zhang,Rong Liang,Rui Meng,Yuchen Fei,Haolin Song,Chenghao Ying,Yan Dai,Yaya Wang,Iman Ei-Hariry,Guoqiang Wang,Weiwen Ying,Zhengbo Song","doi":"10.1158/2159-8290.cd-25-1346","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-1346","url":null,"abstract":"KRAS G12D is the most prevalent subtype of KRAS mutation across solid tumors, but no drug is available in the clinic. RNK08954 is a potent and selective KRAS G12D inhibitor that inhibits proliferation of KRAS G12D-mutant cells and demonstrates significant tumor regressions in mouse xenograft models while inhibiting KRAS-mediated signaling. The in vivo effects of RNK08954 are explained by its unique pharmacokinetic (PK) profile and significantly prolonged retention time in tumor tissues. RNK08954 shows synergy with immune check blockade (ICB). In a Phase 1a study, the median follow-up was 4.85 months for 36 evaluable patients. In patients with non-small cell lung cancer (NSCLC), the objective response rate (ORR, unconfirmed) is 58.33%, and in patients with pancreatic ductal adenocarcinoma (PDAC) the ORR (unconfirmed) was 33.33% in the 1000-1200mg cohort. This study supports the clinical potential of RNK08954 in patients with KRAS G12D mutation either as a single agent or in combination.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"30 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-21DOI: 10.1158/2159-8290.CD-RW2026-010
{"title":"Newly Described Cell Death Pathway May Provide Therapeutic Opportunity.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-010","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-RW2026-010","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-21DOI: 10.1158/2159-8290.cd-nw2026-0004
A recent study shows that CD27 agonism can improve the efficacy and durability of vaccine-induced antitumor responses in HER2+ breast cancer. The outcomes may pave the way for approaches to improve the efficacy and durability of tumor antigen vaccines.
{"title":"Targeting CD27 Boosts Vaccine-induced Immune Memory.","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0004","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0004","url":null,"abstract":"A recent study shows that CD27 agonism can improve the efficacy and durability of vaccine-induced antitumor responses in HER2+ breast cancer. The outcomes may pave the way for approaches to improve the efficacy and durability of tumor antigen vaccines.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"52 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146015363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：